$525.73+16.04% · 3M
Moving avg
1W+8.44%
1M+9.47%
3M+16.04%
6M+13.98%
YTD+16.28%
1Y+35.58%
3Y+50.48%
5Y+169.87%
52-week range
$362.5095% of range$533.67
Company health
Value0/6
Growth6/6
Profitability6/6
Health6/6
Dividend0/6
Bull vs bear
Strengths
- Analyst consensus is "Buy"
- Strong 33% net margin
- High return on equity (2393%)
- Revenue compounding 32% a year
- Net cash on the balance sheet
Risks
No obvious red flags from the metrics.
Key statistics
Valuation
Market cap
$133.43B
Enterprise value
$117.65B
P/E ratio (TTM)
28.06x
P/S ratio (TTM)
9.89x
EV/EBITDA
21.82x
Per share & returns
EPS (TTM)
$17.07
Dividend yield
0.00%
Beta (1Y)
0.29
30-day change
+9.47%
Trading
Volume (24h)
1.02M
Previous close
$529.65
Shares outstanding
253.81M
About Vertex Pharmaceuticals Incorporated
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Symbol
VRTX
Vertex Pharmaceuticals Incorporated is a large-cap healthcare company in the Biotechnology industry. Its shares are listed on NASDAQ (United States) and trade under the ticker VRTX.
Frequently asked questions
What is Vertex Pharmaceuticals Incorporated's market cap?
Vertex Pharmaceuticals Incorporated (VRTX) has a market capitalization of $133.43B.
What is Vertex Pharmaceuticals Incorporated's P/E ratio?
Vertex Pharmaceuticals Incorporated trades at a price-to-earnings (P/E) ratio of 28.06.
What exchange does VRTX trade on?
VRTX trades on NASDAQ.
Appears in
Compare & explore
Eli Lilly and CompanyLLY
$1,220.51+0.45%
$1.15T cap
Johnson & JohnsonJNJ
$260.86+0.41%
$628.65B cap
AbbVie Inc.ABBV
$248.66-0.57%
$439.33B cap
UnitedHealth Group IncorporatedUNH
$405.59+0.85%
$368.33B cap
Roche Holding AGSWX: ROP
CHF 365.50-0.92%
$357.56B cap
Merck & Co., Inc.MRK
$132.93+1.92%
$328.31B cap
Novartis AGSWX: NOVN
CHF 124.20-1.32%
$290.12B cap
AstraZeneca PLCLON: AZN
£117.02-1.20%
$244.93B cap